SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2007. CA Cancer J Clin 2007; 57:4366.
  • 2
    Ries LAG, Harkins D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2003. Bethesda, MD: National Cancer Institute; 2006. Available at: http://seer.cancer.gov/csr/1975_2003/. Accessed September 15, 2006.
  • 3
    Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997; 80:11981120.
  • 4
    American College of Surgeons. Public Access NBCD Survival Reports. Available at: http://web.facs.org/ncdbr/survival7.cfm. Accessed August 4, 2006.
  • 5
    Bukowski RM. Immunotherapy in renal cell carcinoma. Oncology (Williston Park) 1999; 13:801810.
  • 6
    McDermott DF, Regan M, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133141.
  • 7
    Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer. J Clin Oncol 2003; 16:31273132.
  • 8
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant interferon alfa-2b, or both in metastatic renal cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338:12721278.
  • 9
    Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999; 353:1417.
  • 10
    Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17:28592867.
  • 11
    Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 1:CD001425.
  • 12
    Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of a prospective randomized trial. J Clin Oncol 2005; 23:380s. Abstract 4511.
  • 13
    Negrier S, Perold D, Ravaud A, et al. Is intravenous (iv) IL-2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY Duo trial [abstract]. J Clin Oncol 2006; 24:18s. Abstract 4536.
  • 14
    Kaufman JJ. Cancer of the urogenital tract: kidney. Reasons for nephrectomy: palliative and curative. JAMA 1968; 204:607608.
  • 15
    Montie JE, Stewart BH, Straffon RA, et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977; 3:272275.
  • 16
    Wood CG. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am 2003; 30:581588.
  • 17
    Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:16551659.
  • 18
    Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 2001; 358:966970.
  • 19
    Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171:10711076.
  • 20
    Kierney PC, Van Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1994; 1:345352.
  • 21
    Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16:22612266.
  • 22
    Volkmer BG, Gschwend JE. Value of metastases surgery in metastatic renal cell carcinoma [in German]. Urologe 2002; 41:225230.
  • 23
    Ghavamian R, Klein KA, Stephens DH, et al. Renal cell carcinoma metastatic to the pancreas: clinical and radiological features. Mayo Clin Proc 2000; 75:581585.
  • 24
    Sohn TA, Yeo CJ, Cameron JL, et al. Renal cell carcinoma metastatic to the pancreas: results of surgical management. J Gastrointest Surg 2001; 5:346351.
  • 25
    Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol 2003; 10:705710.
  • 26
    Lau WK, Zincke H, Lohse CM, et al. Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. BJU Int 2003; 91:775779.
  • 27
    Law CH, Wei AC, Hanna SS, et al. Pancreatic resection for metastatic renal cell carcinoma: presentation, treatment, and outcome. Ann Surg Oncol 2003; 10:922926.
  • 28
    Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000; 164:322325.
  • 29
    Schrodter S, Hakenberg OW, Manseck A, et al. Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol 2002; 167:16301633.
  • 30
    Grabmaier K, A de Weijert MC, Verhaegh GW, et al. Strict regulation of CAIX (G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004; 23:56245631.
  • 31
    Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9:802811.
  • 32
    Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal cell carcinoma. J Urol 2004; 171:24612466.
  • 33
    Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11:37143721.
  • 34
    Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:10291039.
  • 35
    Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:425.
  • 36
    Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103:159165.
  • 37
    Watanabe Y, Lee SW, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 1997; 14:20252032.
  • 38
    Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:43684380.
  • 39
    Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23:10281043.
  • 40
    Kourembanas S, Hannan RL, Faller DV. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 1990; 86:670674.
  • 41
    Kuwabara K, Ogawa S, Matsumoto M, et al: Hypoxia-mediated induction of acidic/basicfibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995; 92:46064610.
  • 42
    Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90:43044308.
  • 43
    Gunaratnam L, Morley M, Franovic A, et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 2003; 278:4496644974.
  • 44
    de Paulsen N, Brychzy A, Fournier MC, et al. Role of transforming growth factor-alpha in von Hippel–Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001; 98:13871392.
  • 45
    Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:45934599.
  • 46
    Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427434.
  • 47
    Bukowski RM, Kabbinavar F, Figlin RA, et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2006; 24 (suppl):4523a. Abstract 4523.
  • 48
    Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:1624.
  • 49
    Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:25162524.
  • 50
    Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2006; 24 (suppl):LBA3. Abstract LBA3.
  • 51
    Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of sorafenib (BAY 43–9006)-an oral multi-kinase inhibitor-in patients with advanced RCC [abstract]. Proc Am Soc Oncol 2005;23. Abstract 4510.
  • 52
    Hudes G, Carducci M, Tomczak P, et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) [abstract]. J Clin Oncol 2006; 24 (suppl):LBA4. Abstract LBA4.
  • 53
    Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289296.
  • 54
    Hainsworth JD, Sosman DR, Spigel RC, et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma. J Clin Oncol 2005; 31:78897896.
  • 55
    Rini BI, Halabi S, Taylor J, et al. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004; 10:25842586.
  • 56
    Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327337.
  • 57
    Mulder PH, J Roigas J, S Gillessen S, et al. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2006; 24 (suppl):4529. Abstract 4539.
  • 58
    Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2006; 24 (suppl):4522. Abstract 4522.
  • 59
    Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001; 8:219225.
  • 60
    Wilhelm S, Carter C, Tang L, et al. BAY 43–9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Proc Am Assoc Cancer Res 2003; 44:A78.
  • 61
    Ratain MG, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:25052512.
  • 62
    Eisen T, Bukowski RM, Staehler M, et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival [abstract]. J Clin Oncol 2006; 24 (suppl):4524. Abstract 4524.
  • 63
    Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2006; 24 (suppl):4501. Abstract 4501.
  • 64
    Gollob J, Richmond T, Jones J, et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC) [abstract]. J Clin Oncol 2006; 24 (suppl):4538. Abstract 4538.
  • 65
    Ryan CW, Goldman BH, Lara PN, et al. Sorafenib plus interferon-a2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412 [abstract]. J Clin Oncol 2006; 24 (suppl):4525. Abstract 4525.
  • 66
    Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor inhibition. Clin Cancer Res 2001; 7:17581764.
  • 67
    Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22:70047014.
  • 68
    Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 5:909918.
  • 69
    Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98:1031410319.
  • 70
    Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832841.
  • 71
    Amato RJ, Misellati A, Khan M, Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) [abstract]. J Clin Oncol 2006; 24 (suppl):4530. Abstract 4530.
  • 72
    Choueiri TK, Dreicer R, Rini BI, et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma (MRCC) [abstract]. J Clin Oncol 2006; 24 (suppl):4539. Abstract 4539.
  • 73
    Marsh L, Khan M, Needle M, Amato R. Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC) [abstract]. J Clinc Oncol 2006; 24 (suppl):4533. Abstract 4533.
  • 74
    Figlin RA, Kondagunta GV, Yazji S, et al. Phase II study of volociximab (M200), an a5fl1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC) [abstract]. J Clin Oncol 2006; 24 (suppl):4535. Abstract 4535.
  • 75
    Ravaud A, Gardner J, Hawkins R, et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2006; 24 (suppl):4502. Abstract 4502.
  • 76
    Hutson TE, Bukowski RM. A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clin Genitourin Cancer 2006; 4:296298.
  • 77
    Rini BI, Rixe O, Bukowski RM, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) [abstract]. J Clin Oncol 2005; 23 (suppl):4509. Abstract 4509.